From a functional viewpoint, several different types of chloride channels showing different electrophysiological and regulatory characteristics have been described. These can be loosely grouped into five categories: cAMP-, calcium-, volume- and voltage-activated chloride channels as well as ligand-gated chloride channels. In addition to being differentially regulated, chloride channels can be discriminated by their molecular structure.

To date, nearly 40 different genes (including those for ligand-gated chloride channels: GABA(A), GABA(C) and glycine) have been cloned and, when expressed in an appropriate expression system, shown to increase a chloride conductance. In addition, there are a number of other candidates that are thought to be either chloride channels or regulators of chloride channels, since they also give rise to a chloride current when expressed.

Such proteins include: phospholemman (a 72-amino acid sarcolemmal protein suggested to express an anion selective channel which mediates taurine efflux during regulatory volume decrease), p-glycoprotein (a member of the 'ATP-Binding Cassette' (ABC) superfamily of transporters), and pICln (a soluble cytosolic protein that has no significant homology with the sequence of any known transporter or ion channel). However, parchorin, p64 and the related chloride intracellular channel (CLIC) proteins are widely expressed candidates for novel, auto-inserting, self-assembling intracellular anion channels. Other chloride channels uncharacterized at a molecular level also exist, such as a the background anionic current (IAB) in rat and guinea pig ventricular myocytes that plays a role in regulating action potential duration.

A number of chloride channel blockers have been identified, although none of these are used therapeutically. These blockers represent a selection of heterogeneous molecules, including the stilbene disulphonate derivatives such as the amino reactive agent 4-acetamido-4'-isothiocyanato-stilbene-2,2'-disulfonic acid (SITS) and the diphenylamine-2-carboxylate (DPC) derivatives such as 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB). Indyanyl oxyacetic acid (IAA-94) is an example of a third group of chloride channel blockers. In addition, the triphenyl-nonsteroidal anti-estrogens tamoxifen and clomiphene, the antidepressants fluoxetine and imipramine, and pyrethroids represent other classes of chloride channel blockers.

To date, compounds identified with putative chloride channel activating properties include: NS004 (a substituted benzimidazolone) a number of xanthine derivatives (e.g. 3,7-dimethyl-1-propyl xanthine), genistein and MPB-07 (reported to activate CFTR), acid-activated omeprazole (activates ClC-2), tamoxifen (activates a large conductance chloride channel) and tefluthrin (activates IAB). All the chloride channel modulators noted above display fairly low affinity (mid µM-mM) and possess poor selectivity for the different classes of chloride channel. For example, DIDS is also a potent inhibitor of anion exchangers and of the potassium/chloride co-transporter. Similarly, NPPB is an effective inhibitor of this co-transporter and the lactate transporter. However, recent findings suggest that it should be possible to develop agents specific for a given type of chloride channel since it appears that some blockers may discriminate between calcium-activated chloride channels and CFTR. For example, the CFTR channel is blocked by glibenclamide (originally thought to be specific for certain types of potassium channel), but is relatively insensitive to DIDS, NPPB or tamoxifen.

Among the most recent modulators of chloride secretion in epithelia, calixarene derivatives have been shown to reversibly block outwardly rectifying chloride channels at subnanomolar concentrations without effects on CFTR. Cyclic AMP has been reported to inhibit volume-regulated chloride channels from mammalian heart. Calcium-activated and volume-activated chloride channels on the other hand are both blocked by DIDS and NPPB, although tamoxifen and clomiphene act selectively on volume-activated channels.

With regard to potency, chlorotoxin (a 36-amino acid peptide isolated from the venom of the scorpion Leiurus quinquestriatus) has been reported to block small conductance chloride channels with a much higher affinity (nM) than the blockers described above. Recent work has also identified a number of novel phenyl derivatives containing acid groups such as N-(3'-trifluoromethylphenyl)-N'-(2-carboxyphenyl)urea with reported blocking capacities in the submicromolar range. Interestingly, mibefradil, a T-type calcium channel blocker, has also been reported to block chloride channels in the submicromolar range.

The Table below contains accepted modulators and additional information. For a list of additional products, see the "MAterials" section below.


a) Ligand-gated chloride channels (i.e. those regulated by GABA and glycine) are discussed on the GABAC Receptors and Glycine Receptors pages, respectively.

b) Large 20-50pS outwardly-rectifying chloride channels underlie volume-activated chloride currents in various preparations. These may belong to an unknown gene family. Recent evidence has shown that ClC-3 may be responsible for native swelling-activated chloride currents in many mammalian cells, but not in human. Swelling-activated chloride currents are known to be regulated by phosphorylation and dephosphorylation.


9-AC: 9-Aminocamptothecin
DIDS: 4,4′ Diisothiocyanatostilbene-2,2′ -disulfonic acid
DPC: Diphenylamine-2-carboxylate
IAA-94: Indyanyl oxyacetic acid
NPPB: 5-Nitro-2-(3-phenylpropylamino) benzoic acid
NS004: 5-Trifluoromethyl-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benzimidazo le-2-one
SITS: 4-Acetamido-4′-isothiocyanato-stilbene-2,2′-disulfonic acid



Baumgarten CM, Clemo HF. 2003. Swelling-activated chloride channels in cardiac physiology and pathophysiology. Progress in Biophysics and Molecular Biology. 82(1-3):25-42.
Becq F, Mettey Y, Gray MA, Galietta LJV, Dormer RL, Merten M, Métayé T, Chappe V, Marvingt-Mounir C, Zegarra-Moran O, et al. 1999. Development of Substituted Benzo[c]quinolizinium Compounds as Novel Activators of the Cystic Fibrosis Chloride Channel. J. Biol. Chem.. 274(39):27415-27425.
Chappe V, Mettey Y, Vierfond JM, Hanrahan JW, Gola M, Verrier B, Becq F. 1998. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. 123(4):683-693.
Clément Y. 1996. Structural and pharmacological aspects of the GABAA receptor: Involvement in behavioral pathogenesis. Journal of Physiology-Paris. 90(1):1-13.
Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R. 2002. X-ray structure of a ClC chloride channel at 3.0?Å reveals the molecular basis of anion selectivity. Nature. 415(6869):287-294.
Huang F, Wong X, Jan LY. 2012. International Union of Basic and Clinical Pharmacology. LXXXV: Calcium-Activated Chloride Channels. Pharmacol Rev. 64(1):1-15.
Hume JR, Duan D, Collier ML, Yamazaki J, Horowitz B. 2000. Anion Transport in Heart. Physiological Reviews. 80(1):31-81.
Jentsch TJ, Stein V, Weinreich F, Zdebik AA. 2002. Molecular Structure and Physiological Function of Chloride Channels. Physiological Reviews. 82(2):503-568.
Kozlowski, R.Z., . 1999. Chloride channels: Potential therapeutic targets., In Chloride Channels Kozlowski, R.Z., ed., pp., ISIS Medical Media Ltd, Oxford..177-186.
Large WA, Wang Q. 1996. Characteristics and physiological role of the Ca(2+)-activated Cl- conductance in smooth muscle. American Journal of Physiology-Cell Physiology. 271(2):C435-C454.
Miller C. 2006. ClC chloride channels viewed through a transporter lens. Nature. 440(7083):484-489.
Nilius B, Eggermont J, Voets T, Droogmans G. 1996. Volume-activated Cl? channels. General Pharmacology: The Vascular System. 27(7):1131-1140.
Nishizawa T, Nagao T, Iwatsubo T, Forte JG, Urushidani T. 2000. Molecular Cloning and Characterization of a Novel Chloride Intracellular Channel-related Protein, Parchorin, Expressed in Water-secreting Cells. J. Biol. Chem.. 275(15):11164-11173.
Rajendra S, Lynch JW, Schofield PR. 1997. The glycine receptor. Pharmacology & Therapeutics. 73(2):121-146.
Sieghart W, Ramerstorfer J, Sarto-Jackson I, Varagic Z, Ernst M. 2012. A novel GABAA receptor pharmacology: drugs interacting with the ?+?- interface. 166(2):476-485.
Sieghart W. 1992. GABAA receptors: ligand-gated Cl? ion channels modulated by multiple drug-binding sites. Trends in Pharmacological Sciences. 13446-450.
Wolstenholme AJ. 2012. Glutamate-gated Chloride Channels. J. Biol. Chem.. 287(48):40232-40238.

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.